|Bid||7.56 x 2200|
|Ask||7.63 x 1200|
|Day's Range||7.54 - 7.61|
|52 Week Range||6.65 - 17.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.20|
Seres Therapeutics, Inc. today announced that the Company will host a Microbiome R&D Day on Thursday, May 24, 2018, from 8:00 a.m.–10:30 a.m. ET in New York, NY.
The Cambridge, Massachusetts-based company said it had a loss of 69 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Seres Therapeutics, Inc. , today reported first quarter financial results and provided operational updates.
Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on May 9, 2018 at 8:30 a.m. ET to discuss first quarter 2018 financial results and provide a general business update.
NEW YORK, April 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Seres Therapeutics, Inc. today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology 1 will be presented today by Sceneay et al in the late breaking poster session at the 2018 American Association for Cancer Research Annual Meeting in Chicago.
Seres Therapeutics, Inc. today announced it will present at each of the following upcoming healthcare conferences:
Seres Therapeutics, Inc. , a leading microbiome therapeutic development company developing a novel class of biological drugs, today reported fourth quarter and full year 2017 financial results and provided operational and strategic updates.
NEW YORK, NY / ACCESSWIRE / March 8, 2018 / Seres Therapeutics Inc (NASDAQ: MCRB ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018 at 8:00 AM Eastern Time. ...
Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on March 8, 2018 at 8:00 a.m. ET to discuss fourth quarter 2017 results and provide a general business update.
NEW YORK, Feb. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AeroVironment, ...
Seres Therapeutics, Inc., today announced the appointment of Eric D. Shaff to the additional role of Chief Operating Officer. Mr. Shaff has been Executive Vice President and Chief Financial Officer since joining the Company in November 2014, and he will continue to retain both positions.
Seres Therapeutics, Inc., today announced initial microbiome results from its Phase 1b study of SER-287, a microbiome therapeutic candidate derived from healthy individuals, in patients with mild-to-moderate Ulcerative Colitis who were failing current therapies.
Seres Therapeutics, Inc. today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11 at 8:30 a.m.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Seres Therapeutics, Inc. Here are 5 ETFs with the largest exposure to MCRB-US. Comparing the performance and risk of Seres Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Seres Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
Seres Therapeutics, Inc., today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to microbiome therapeutic candidate SER-287 for the treatment of Ulcerative Colitis in pediatric patients.
CAMBRIDGE, Mass., Nov. 14, 2017 /PRNewswire/ -- Torque, an immuno-oncology company developing Deep Primed™ cell therapies that direct and evoke immune responses in the tumor microenvironment, today announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed with $25 million in Series A capital by Flagship Pioneering. The Torque platform makes it possible to anchor powerful stimulatory cytokines, antibodies, and small molecules directly to immune cells to direct their activity and increase their efficacy and durability in the "hostile" tumor microenvironment, without systemic exposure.
Scientists at MD Anderson Cancer Center in Texas recently showed that the makeup of a person’s microbiome — the trillions of bacteria living in the gut — could help determine whether immunotherapy treatments will work or fail. Now researchers there are planning to further test that concept through a partnership with Seres Therapeutics (MCRB), a Cambridge startup developing microbiome drugs, as well as the Parker Institute, a research collaboration formed by tech entrepreneur Sean Parker. Seres, MD Anderson and the Parker Institute announced Tuesday that they will launch a trial in which patients with advanced metastatic melanoma will either receive a fecal transplant, a live biologic provided by Seres, or a placebo.